Emicizumab promotes factor Xa generation on endothelial cells
Until recently, the treatment of hemophilia A relied on factor (F)VIII replacement. However, up to one-third of patients with severe hemophilia A develop neutralizing alloantibodies that render replacement therapies ineffective. The development of emicizumab, a bispecific antibody that partially mim...
Saved in:
Published in | Journal of thrombosis and haemostasis Vol. 22; no. 6; pp. 1605 - 1615 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
England
Elsevier Inc
01.06.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!